Navigation Links
PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress

BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- Albert Liou, Corporate Vice President and General Manager, Asia-Pacific Region, at PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will present "What Can China Really Deliver in Terms of Cost and Efficiency Savings in Running Clinical Trials?" at the 7th Annual Partnerships in Clinical Trials Congress and Exhibition, to be held November 4 - 7, 2008 at the Estrel Convention Center in Berlin, Germany. PAREXEL is a sponsor of the congress.

During PAREXEL's presentation, taking place on Wednesday, November 5 at 3:25 p.m. CET, Mr. Liou will explore various issues and considerations for conducting clinical research in China, including approaches to identify well-established investigator sites, the extent of improvements in quality and innovation, strategies for overcoming regulatory hurdles, and ways to ensure compliance with U.S. Food and Drug Administration (FDA), European Medicines Agency (EMEA), and GxP standards.

With 13 locations throughout the Asia-Pacific region, including offices in Beijing, Hong Kong, and Shanghai, China, PAREXEL has had a long-term commitment to providing a high level of standardization and quality clinical development services in these geographies. PAREXEL helps clients address key challenges in conducting studies in the Asia-Pacific region and globally, including accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality.

For over 25 years, PAREXEL has been a proven and committed partner to pharmaceutical, biotechnology, and medical device companies looking to bring innovative new products to market. PAREXEL has extensive experience in providing comprehensive worldwide services to companies of all sizes. With deep expertise and capabilities in consulting, clinical research, eClinical technologies, and medical communications, PAREXEL has helped drive the success of thousands of its clients' development programs, and has assisted clients in getting their products to patients in need. Attendees at the 7th Annual Partnerships in Clinical Trials Congress and Exhibition 2008 can visit with PAREXEL's experts at Booth #324 in the exhibit hall to discuss these capabilities.

For more information about PAREXEL's Clinical Research Services visit:

About PAREXEL International

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has over 9,180 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Annual Report on Form 10-K for the Fiscal Year ended June 30, 2008 as filed with the SEC on August 28, 2008, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.


Jennifer Baird Rebecca Passo

Senior Director of Public Relations SHIFT Communications

PAREXEL International Tel: +617-681-1817

Tel: +781-434-4409 Email:


SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
2. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
3. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
4. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
5. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
6. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
7. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
8. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
9. PAREXEL Closes the Acquisition of ClinPhone
10. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
11. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
Post Your Comments:
(Date:11/24/2015)...  Clintrax Global, Inc., a worldwide provider of clinical research services ... that the company has set a new quarterly earnings record in ... growth posted for Q3 of 2014 to Q3 of 2015.   ... , with the establishment of an Asia-Pacific ... United Kingdom and Mexico , ...
(Date:11/24/2015)... ... 2015 , ... This fall, global software solutions leader SAP and AdVenture Capital ... and pitch their BIG ideas to improve health and wellness in their schools. , ... win the title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
(Date:11/24/2015)... -- Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting ... Israel time, at the law offices of ... th Floor, Tel Aviv, Israel . ... Izhak Tamir to the Board of Directors; , election of ... approval of an amendment to certain terms of options granted to our ...
Breaking Biology Technology:
(Date:11/18/2015)... New York , November 18, 2015 ... Market Research has published a new market report titled ... Growth, Trends, and Forecast, 2015 - 2021. According to the ... in 2014 and is anticipated to reach US$29.1 bn ... to 2021. North America ...
(Date:11/16/2015)... Calif. , Nov 16, 2015  Synaptics ... of human interface solutions, today announced expansion of ... TouchView ™ touch controller and display driver ... revolution of smartphones. These new TDDI products add ... TD4100 (HD resolution), TD4302 (WQHD resolution), and TD4322 ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):